
Journal of medicinal chemistry p. 603 - 605 (1982)
Update date:2022-09-26
Topics:
Woo
Baker
erythro-1,6-Dihydro-6-(hydroxymethyl)-9-(2-hydroxy-3-nonyl)purine (4) was synthesized as a potential adenosine deaminase inhibitor, which combines in a single molecule two structural moieties, each of which possesses high affinity to a different region of the enzyme, the catalytic region and an auxiliary binding region which is specific for erythro-9-(2-hydroxy-3-nonyl)adenine (1). The potency of 4 (Ki = 1.2 x 10(-5) M) is about one-seventeenth that of erythro-9-(2-hydroxy-3-nonyl)purine (2; Ki = 6.8 x 10(-7) M), which contains only one high-affinity moiety. The mutually interfering rather than reinforcing effects of the two moieties may indicate that lack of simultaneous binding and thus provide insight into the relative geometry of the two binding regions of the enzyme.
View MoreZhengzhou Institute of Chiral Pharmer Research Co., Ltd.
Contact:86-371-55219111
Address:15 Floor, 2 Building, Central China Technovalley, Zhongyuan West Road
Tianjin SPHINX SCIENTIFIC LAB.
Contact:+86-022-66211289
Address:Tianda high-tech Park. No.80,the 4th Avenue
Shanghai Yingrui Biopharma Co., Ltd
Contact:021-3358 8661*8003
Address:shanghai
Contact:0086-22-23410962
Address:17-201, Ningfuli, Shuishanggongyuandong road,Nankai district, Tianjin, China
Hangzhou J&H Chemical Co., Ltd.
website:http://www.jhechem.com/
Contact:+86-571-87396432
Address:No.200 Zhenhua Rd.Xihu Industrial Park, Hangzhou 310030, China
Doi:10.1016/S0040-4039(00)77774-4
(1980)Doi:10.1002/jhet.5570180838
(1981)Doi:10.1016/0223-5234(89)90087-1
(1989)Doi:10.1002/ardp.19823150309
(1982)Doi:10.1016/0040-4039(92)80020-K
(1992)Doi:10.1016/S0040-4039(00)73063-2
(1994)